ProCE Banner Activity

Phase Ib/II Study of Neoadjuvant Chemotherapy + Pembrolizumab for Muscle-Invasive Urothelial Cancer

Capsule Summary
Conference Coverage

Results from this phase Ib/II trial suggest neoadjuvant therapy with chemotherapy plus pembrolizumab is effective and well-tolerated for patients with muscle-invasive urothelial cancer.

Released: February 22, 2023

Expiration: February 21, 2024


Provided by

ProCE Banner


This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.